In recognition of her extraordinary contributions, Sharon has been inducted into the Montana Bioscience Hall of Fame, a fitting tribute to her enduring impact on our bioscience community. And to further honor her legacy, we are proud to announce the creation of the Sharon Peterson STEM Scholarship.
Eye-tracking Tech Detects Impairment
Device developed by Missoula company Gaize (gaize.ai) could help to keep people safe at work and on the road.
C2M Beta Cohort Applications Open
2M Beta is a 12-week program delivering the foundational and modern skills required to transform influential ideas into thriving businesses. With access to more professional expertise, more state-of-the-art technology and more community resources, C2M Beta was founded with the mission to connect local entrepreneurs to more!
SPI Pharma, Inc. and Inimmune, Corp. Partner to Develop and Commercialize Innovative Vaccine Adjuvant Systems
SPI Pharma, Inc. a global leader in biopharmaceutical excipient and adjuvant systems, and Inimmune, Corp., a pioneering biotechnology company specializing in the discovery and development of innate immune modulators, announce an agreement in principle to create a strategic collaboration to develop and commercialize advanced adjuvant systems for vaccine development. This collaboration leverages Inimmune’s world-class expertise in adjuvant formulation and immunotherapeutics and SPI Pharma’s extensive manufacturing and global commercial capabilities.
NIAID Targets Transport System as Lyme Disease Treatment
NIAID scientists and colleagues are investigating a potential treatment strategy against Lyme disease that would directly suppress Borrelia burgdorferi, the bacterium that causes the disease. If successful, their idea could reduce or end aggressive broad-spectrum antibiotic treatments that can be drawn-out and destroy the body’s helpful bacteria.
Golden Helix Secures CE Mark for the European Union
Golden Helix, Inc., a leading provider of clinical bioinformatics solutions, is pleased to announce that it has received CE mark approval for its genetic analysis platform VarSeq Suite. This significant regulatory milestone paves the way for the expansion of Golden Helix’s advanced genetic analytics products to the European market, ensuring compliance with the European Union’s health, safety, and environmental protection standards.
NIH study shows chronic wasting disease unlikely to move from animals to people
A new study of prion diseases, using a human cerebral organoid model, suggests there is a substantial species barrier preventing transmission of chronic wasting disease (CWD) from cervids—deer, elk and moose—to people.
Inimmune announces successful Phase 1 clinical results for disease modifying allergy treatment, INI-2004
Inimmune, a leading clinical stage biotech company focused on the development of novel vaccine adjuvants, immunotherapies and delivery systems, has announced the top line results from its Phase 1b Multiple Ascending Dose (MAD) study of INI-2004 in people suffering with Allergic Rhinitis.
Montana State scientists’ research on RNA editing illuminates possible lifesaving treatments for genetic diseases
A team at Montana State University published research this week that shows how RNA, the close chemical cousin to DNA, can be edited using CRISPRs. The work reveals a new process in human cells that has potential for treating a wide variety of genetic diseases.
Postdoctoral researchers Artem Nemudryi and Anna Nemudraia conducted the research alongside Blake Wiedenheft, professor in the Department of Microbiology and Cell Biology in MSU’s College of Agriculture. The paper, titled “Repair of CRISPR-guided RNA breaks enables site-specific RNA excision in human cells,” was published online Thursday in the journal Science and constitutes the latest advance in the team’s ongoing exploration of CRISPR applications for programmable genetic engineering.